Ralexar Therapeutics
Malvern
About Ralexar Therapeutics
Ralexar Therapeutics company is developing topical and systemic therapies based on the Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis. Alexar changes its name to Ralexar Therapeutics. The company was founded in 2013 and is based in Malvern, Pennsylvania.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $41.6M
- Last round: Series Unknown (Jun 2017)
- Website: ralexar.com
- Phone: 484-318-2988
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Canonical: https://fsome.com/organization/ralexar-therapeutics-144273 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.